Business News

Lilly and Innovent Announce Global Expansion of TYVYT Licensing Agreement

INDIANAPOLIS and SUZHOU, China, Aug. 18, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Innovent Biologics, Inc. (HKEX: 01801) today announced a global expansion of their strategic alliance for TYVYT® (sintilimab injection), an anti-PD-1 monoclonal antibody immuno-oncology medicine that was co-developed by Innovent and Lilly in China. In 2019, Lilly and Innovent began commercializing TYVYT in China after being granted marketing approval …

Read More »

Gilead Sciences and Tango Therapeutics to Expand Strategic Oncology Collaboration

FOSTER CITY, Calif. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Tango Therapeutics today announced an expanded strategic collaboration focused on the discovery, development and commercialization of innovative targeted immune evasion therapies for patients with cancer. Under the expanded multi-year collaboration, which builds on an agreement signed in 2018, …

Read More »

Bristol Myers Squibb Announces Exclusive Global License for Dragonfly’s IL-12 Investigational Immunotherapy Program

NEW YORK & WALTHAM, Mass.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) and Dragonfly Therapeutics, Inc. (“Dragonfly”), today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted the global exclusive license to Dragonfly’s interleukin-12 (IL-12) investigational immunotherapy program, including its extended half-life cytokine DF6002. DF6002 …

Read More »

Thermo Fisher Scientific Signs Oncology Companion Diagnostic Agreement with Hengrui Therapeutics

CARLSBAD, Calif., Aug. 17, 2020 /PRNewswire/ — Thermo Fisher Scientific has signed a companion diagnostic (CDx) agreement with Hengrui Therapeutics, Inc. (HTI), a U.S. subsidiary of Chinese pharmaceutical company Jiangsu Hengrui Medicine Co., Ltd. (JHM), to develop a CDx that will leverage the Oncomine Precision Assay, which runs on the …

Read More »

OneOncology and Foundation Medicine Unveil First-of-its-Kind Partnership to Advance Personalized Medicine at Community Oncology Practices

CAMBRIDGE, Mass. & NASHVILLE, Tenn.–(BUSINESS WIRE)–Foundation Medicine, Inc. and OneOncology today announced a new joint initiative that is intended to better enable OneOncology partner practice physicians to unlock the potential of precision oncology through comprehensive genomic profiling (CGP) and research, informed by CGP and real world evidence. This unique partnership will …

Read More »

Sanofi to Acquire Principia Biopharma for $3.4 Billion

PARIS and SOUTH SAN FRANCISCO, Calif. – August 17, 2020 – Sanofi and Principia Biopharma Inc. (NASDAQ: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Principia for $100  per share in …

Read More »

Thermo Fisher’s $12.5 Billion Deal to Acquire Qiagen Falls Through

WALTHAM, Mass., Aug. 13, 2020 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its offer to acquire all of the ordinary shares of QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has lapsed. Based on information provided by the settlement agents …

Read More »

Galapagos Partners with Scipher Medicine to to Identify Novel Drug Targets for Treatment of Inflammatory Bowel Disease

Mechelen, Belgium and Boston, USA; 12 August 2020 – Galapagos NV (Euronext & Nasdaq: GLPG) and Scipher Medicine (Scipher), a Boston based privately held precision medicine company focused on autoimmune diseases, today announce a collaboration to advance novel drug targets identified by Scipher for the treatment of inflammatory bowel disease …

Read More »

Janssen and GenCentric Enter Research Collaboration on Genomic Drug Response Biomarkers for Non-Muscle Invasive Bladder Cancer

DURHAM, N.C.–(BUSINESS WIRE)–GeneCentric Therapeutics today announced it has entered into a research collaboration with Janssen Research & Development, LLC (Janssen) around RNA-based drug response biomarkers for non-muscle invasive bladder cancer (NMIBC). The research will involve the application of GeneCentric’s advanced RNA-based molecular profiling platform to elucidate potential signatures of disease …

Read More »

Medtronic to Acquire Smart Insulin Pen Company Companion Medical

DUBLIN and SAN DIEGO, Aug. 11, 2020 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the planned acquisition of privately-held Companion Medical, manufacturer of InPen — the only U.S. FDA-cleared smart insulin pen system paired with an integrated diabetes management app on the market. The …

Read More »